EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), including erlotinib and gefitinib, have been proven clinically effective in the treatment of advanced NSCLC harboring EGFR mutations (deletion in exon 19 or L858R) [5].